Article Sidebar
Keywords:
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publication rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Note: If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.
Main Article Content
A comparative study of Klimakt-Heel® and Femolene Ultra in the management of typical climacteric symptoms
Abstract
symptoms’ of varying intensity, including vasomotor reactions, increased perspiration, sleeping problems, mood changes, headaches, joint pains and urogenital problems. The aim of this study was to determine the effectiveness of Femolene Ultra (phytotherapeutic preparation) and Klimakt-Heel® (homeopathic preparation) in the treatment of typical climacteric symptoms. Thirty female volunteers between the ages of 44 and 57 years suffering from climacteric symptoms were recruited and asked to complete the Patient Profi le and Case History Form and to sign a Patient Information and Consent Form. These participants were randomly placed in two groups of fi fteen. One group received Femolene Ultra and the other received Klimakt-Heel® for a period of 12 weeks. The trial was blinded as neither the researcher nor the participant was aware of which treatment was being administered. Blood samples were taken to ascertain the 17ß oestradiol levels before and after the 12-week period. The Kupperman Menopause Index (KMI) was used as a self-report measure and completed at four-weekly intervals. For statistical purposes, the Wilcoxon Signed Rank Test, from the class of non-parametric distribution-free tests, was used. Both products served to decrease the typical climacteric symptoms signifi cantly within the 12-week period. Femolene Ultra decreased the average Kupperman Menopause Index (KMI) score by 63% (26.2 to 16.4) and Klimakt-Heel® decreased the average score by 54% (28.4 to 15.28), although more participants in the Klimakt-Heel® group experienced amelioration of climacteric symptoms. The results are not conclusive, but they do provide an interesting base-line on which further research can be built.
